Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract does not report any research results but mentions researcher affiliations and potential conflicts of interest, indicating the researchers' involvement in various pharmaceutical collaborations.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This research highlights that while JAK inhibitors are effective for various inflammatory conditions, studies raise concerns about increased risks of venous and arterial thromboembolism, and cancer, particularly with tofacitinib and baricitinib, leading to European guidelines recommending caution in high-risk patients.

In this study, researchers examined a patient with ZMYM2::FGFR1 fusion-positive leukemia, finding that Pemigatinib showed efficacy, while Ponatinib resistance was linked to a specific FGFR1 mutation. Other FGFR inhibitors demonstrated high effectiveness in ex vivo assays.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

This study introduces ficlatuzumab, an anti-HGF monoclonal antibody, in combination with gefitinib in a phase 2 trial to address EGFR TKI resistance in Asian NSCLC patients.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This study found that co-administering sasam-Kyeongokgo with gefitinib enhanced gefitinib's anti-tumor activity and exhibited favorable anti-cachexia effects in mice with non-small-cell lung cancer.

This study describes that 65% of patients receiving imatinib mesylate in a patient assistance program experienced skin hypopigmentation, primarily in ethnically Chinese individuals, suggesting variability across populations.

This case report describes the first known instance of hair and eyebrow hyperpigmentation in a patient after seven months of gefitinib treatment for non-small cell lung cancer.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

This study found that in thin cutaneous melanomas, tumor regression is associated with a higher risk of sentinel lymph node involvement.

This article presents a rare case of cicatricial alopecia in a 59-year-old woman after using the epidermal growth factor receptor inhibitor gefitinib.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

Tofacitinib might be used to treat hair loss.

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

In this report, a 61-year-old woman with vitiligo showed significant improvement after tofacitinib treatment but developed lung adenocarcinoma, highlighting potential cancer risks associated with JAK inhibitors.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This case report documents new hair growth in a 57-year-old man with androgenic alopecia after receiving gefitinib treatment for non-small-cell lung cancer.

The researchers reported a case where treatment with tofacitinib improved both hair loss and skin lesions in a patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa over six months, with no recurrence or adverse events during two-year follow-up.

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This report describes a rare case of a non-small-cell lung cancer patient experiencing hair changes after prolonged gefitinib treatment, potentially linked to EGFR inhibition, with limited understanding of its cause.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.